公开(公告)号：EP0876356B1

公开(公告)日：2001-10-31

申请号：EP96941734.4

申请日：1996-12-10

申请人： LABORATOIRE INNOTHERA Société Anonyme

发明人： BOUTHERIN-FALSON, Odile ,  DESQUAND-BILLIALD, Stéphanie ,  FAVROU, Anita ,  FINET, Michel ,  TEMBO, Olivier ,  TORREGROSA, Jean-Luc ,  YANNIC-ARNOULT Sylvie ,  DOMAGALA-LE MARQUER, Florence

IPC分类号： C07D235/02 ,  C07D263/60 ,  C07D413/04 ,  C07D277/84 ,  C07D417/04 ,  A61K31/41 ,  C07C50/00 ,  C07C225/28

CPC分类号： C07D235/02 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/428 ,  C07C46/00 ,  C07C50/24 ,  C07C50/32 ,  C07C225/30 ,  C07C2602/12 ,  C07D263/60 ,  C07D277/84 ,  C07D417/04

摘要： The therapeutical use of tricyclic derivatives and pharmaceutically acceptable salts thereof having general formula (I), for treating diseases related to venous function deficiency and/or inflammatory oedema, is disclosed. In general formula (I), A is a sulphur or oxygen atom or a radical R3N where R3 is a hydrogen atom, a C1-5 alkyl radical or an optionally substituted aromatic or heteroaromatic ring; R1 is either a C1-5 alkyl radical, or a radical R4NH where R4 is a hydrogen atom, a C1-5 alkyl radical or an optionally substituted aromatic or heteroaromatic ring, or an aromatic ring optionally substituted by one or more acceptor or donor groupings, or a heteroaromatic ring having one or more heteroatoms and being optionally substituted by acceptor or donor groupings; and R2 is a hydrogen atom, a halogen atom, a C1-5 alkyl radical, an oxygen atom optionally substituted by a C1-5 alkyl radical, or a radical NR5R5', where each of R5 and R5' is independently a hydrogen or oxygen atom or C1-5 monovalent organic radicals.

公开(公告)号：EP0876356A1

公开(公告)日：1998-11-11

申请号：EP96941734.0

申请日：1996-12-10

申请人： LABORATOIRE INNOTHERA Société Anonyme

发明人： BOUTHERIN-FALSON, Odile ,  DESQUAND-BILLIALD, Stéphanie ,  FAVROU, Anita ,  FINET, Michel ,  TEMBO, Olivier ,  TORREGROSA, Jean-Luc ,  YANNIC-ARNOULT Sylvie ,  DOMAGALA-LE MARQUER, Florence

IPC分类号： A61K31 ,  A61P9 ,  A61P25 ,  A61P31 ,  C07C46 ,  C07C50 ,  C07C225 ,  C07D235 ,  C07D263 ,  C07D277 ,  C07D413 ,  C07D417 ,  C07D307

CPC分类号： C07D235/02 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/428 ,  C07C46/00 ,  C07C50/24 ,  C07C50/32 ,  C07C225/30 ,  C07C2602/12 ,  C07D263/60 ,  C07D277/84 ,  C07D417/04

摘要： The therapeutical use of tricyclic derivatives and pharmaceutically acceptable salts thereof having general formula (I), for treating diseases related to venous function deficiency and/or inflammatory oedema, is disclosed. In general formula (I), A is a sulphur or oxygen atom or a radical R3N where R3 is a hydrogen atom, a C1-5 alkyl radical or an optionally substituted aromatic or heteroaromatic ring; R1 is either a C1-5 alkyl radical, or a radical R4NH where R4 is a hydrogen atom, a C1-5 alkyl radical or an optionally substituted aromatic or heteroaromatic ring, or an aromatic ring optionally substituted by one or more acceptor or donor groupings, or a heteroaromatic ring having one or more heteroatoms and being optionally substituted by acceptor or donor groupings; and R2 is a hydrogen atom, a halogen atom, a C1-5 alkyl radical, an oxygen atom optionally substituted by a C1-5 alkyl radical, or a radical NR5R5', where each of R5 and R5' is independently a hydrogen or oxygen atom or C1-5 monovalent organic radicals.

摘要翻译： 本发明涉及的治疗用途三环的盐和具有通式它们的药学上可接受的盐：其中：A是一个硫原子与氧原子或在R3N基团，其中R 3为氢原子，C1-C5烷基 或substituiertem奥德unsubstituiertem芳香环，或一个substituiertem奥德unsubstituiertem杂ring.R1或者是C1-C5烷基，或在R4NH基团，其中R4是氢原子，C1-C5烷基基团，或一个substituiertem奥德unsubstituiertem 芳香环，或一个substituiertem奥德unsubstituiertem杂芳环，或芳环确实可以或可以不被一个或多个受体或供体基团，或具有一个或多个杂原子的杂芳族环，其可以或可以不通过受体substituiertem被substituiertem 或施主groups.R2是氢原子，卤原子，C1-C5烷基基团，氧原子可以或可以不被一个C1-C5烷基取代的基团，或者在NR 5 R 5，的基团，其中R5和R5是， 海誓山盟的unabhängig，一个HYDROG S原子与氧原子或一价C1-C5有机基团。

公开(公告)号：EP0988036A1

公开(公告)日：2000-03-29

申请号：EP98929494.7

申请日：1998-06-05

申请人： LABORATOIRE INNOTHERA Société Anonyme

发明人： TORREGROSA, Jean-Luc ,  TEMBO, Olivier ,  YANNIC-ARNOULT, Sylvie ,  BOYER-JOUBERT, Cécile ,  FAVROU, Anita ,  FINET, Michel ,  FALSON, Odile ,  DESQUAND-BILLIALD, Stéphanie

IPC分类号： A61K31/435 ,  C07D471/04 ,  C07C50/12 ,  C07D213/73

CPC分类号： C07D213/73 ,  C07D471/04

摘要： The invention concerns the use of teracyclic derivatives of general formula (I) in which independently of one another: R1 is a hydrogen atom, a halogen atom, a C1-C5 alkyl radical, a C1-C5 alkoxy radical or OH, a nitro radical, an amino radical, a C1-C5 amino alkyl radical, a C1-C5 amino dialkyl radical, a C1-C5 thioalkyl radical or SH; R2 is a hydrogen atom, a halogen atom, a C1-C5 alkyl radical, a C1-C5 alkoxy radical, or OH, a nitro radical, an amino radical, a C1-C5 alkyl amino radical, a C1-C5 amino dialkyl radical, a C1-C5 thioalkyl radical or SH; R3 is a hydrogen atom, a halogen atom, a C1-C5 alkyl radical, a C1-C5 alkoxy radical or OH, a nitro radical, an amino radical, a C1-C5 amino alkyl radical, a C-C amino dialkyl radical, a C1-C5 amino thioalkyl radical or SH; n and m are either equal to 0 or to 1, but not independently of each other such that if n is equal to 1 then m is equal to 0, and if n is equal to 0 then m is equal to 1, for obtaining a medicine for treating functional and organic venous insufficiency.

公开(公告)号：EP0876368A1

公开(公告)日：1998-11-11

申请号：EP96941735.0

申请日：1996-12-10

申请人： LABORATOIRE INNOTHERA Société Anonyme

发明人： BOUTHERIN-FALSON, Odile ,  DESQUAND-BILLIALD, Stéphanie ,  FAVROU, Anita ,  FINET, Michel ,  TEMBO, Olivier ,  TORREGROSA, Jean-Luc ,  YANNIC-ARNOULT, Sylvie ,  JOUBERT, Cécile

IPC分类号： A61K31 ,  A61P9 ,  A61P25 ,  A61P29 ,  C07C46 ,  C07D471 ,  C07D487

CPC分类号： C07D471/04 ,  C07C46/00 ,  C07D471/14 ,  C07D487/04 ,  Y02P20/55 ,  C07C50/24

摘要： The therapeutical use of tetracyclic derivatives and pharmaceutically acceptable salts thereof having general formula (I), for treating diseases related to venous function deficiency and/or inflammatory oedema, is disclosed. In general formula (I), X is a carbon atom or a nitrogen atom; T is a carbon atom or a nitrogen atom; L is an oxygen atom or a ketone function protecting grouping; R1 is a hydrogen atom, a halogen atom or a C1-5 alkyl radical; R2 is a hydrogen atom, a halogen atom, a nitro radical or a C1-5 alkyl radical; and n and m are 0 or 1 but not independently so, whereby when n is 1 then m is 0, and vice versa.

公开(公告)号：EP0874844A1

公开(公告)日：1998-11-04

申请号：EP96941736.0

申请日：1996-12-10

申请人： LABORATOIRE INNOTHERA Société Anonyme

发明人： BOUTHERIN-FALSON, Odile ,  DESQUAND-BILLIALD, Stéphanie ,  FAVROU, Anita ,  FINET, Michel ,  TEMBO, Olivier ,  TORREGROSA, Jean-Luc ,  YANNIC-ARNOULT, Sylvie

IPC分类号： A61K31 ,  A61P7 ,  A61P9 ,  A61P25 ,  A61P29 ,  C07D471 ,  C07D498 ,  C07D513

CPC分类号： C07D471/04 ,  A61K31/4745 ,  C07D513/04

摘要： The therapeutical use of tricyclic nitrogen-containing derivatives and pharmaceutically acceptable salts thereof having general formula (I), for treating diseases related to venous function deficiency and/or inflammatory oedema, is disclosed. In general formula (I), A is a sulphur or oxygen atom or a radical R3N where R3 is a hydrogen atom, a C1-5 alkyl radical or an optionally substituted aromatic or heteroaromatic ring; each of X1, X2, X3 and X4 is independently a carbon atom or a nitrogen atom; R1 is a C1-5 alkyl radical, an optionally substituted aromatic ring or an optionally substituted heteroaromatic ring having one or more heteroatoms; and R2 is a hydrogen atom or a C1-5 alkyl radical.

公开(公告)号：EP0866692A1

公开(公告)日：1998-09-30

申请号：EP96941733.0

申请日：1996-12-10

申请人： LABORATOIRE INNOTHERA Société Anonyme

发明人： BOUTHERIN-FALSON, Odile ,  DESQUAND-BILLIALD, Stéphanie ,  FAVROU, Anita ,  FINET, Michel ,  TEMBO, Olivier ,  TORREGROSA, Jean-luc ,  YANNIC-ARNOULT, Sylvie

IPC分类号： C07D295 ,  A61K31 ,  A61P9 ,  A61P17 ,  A61P19 ,  A61P25 ,  A61P29 ,  C07C225 ,  C07C233 ,  C07C243 ,  C07C275 ,  C07D209 ,  C07D213 ,  C07D215 ,  C07D217 ,  C07D237 ,  C07D239 ,  C07D241 ,  C07D311 ,  C07D319

CPC分类号： C07D213/74 ,  C07C225/30 ,  C07C233/32 ,  C07C243/38 ,  C07C275/30 ,  C07D209/08 ,  C07D213/86 ,  C07D215/24 ,  C07D217/02 ,  C07D237/28 ,  C07D237/30 ,  C07D239/74 ,  C07D241/42 ,  C07D295/116 ,  C07D311/22

摘要： The therapeutical use of bicyclic derivatives and pharmaceutically acceptable salts thereof having general formula (I), wherein each of X1, X2, X3 and X4 is independently a carbon atom or a nitrogen atom, with n being 0 or 1; A is selected from an oxygen atom and a carbonyl grouping; each of R1 and R2 is independently either: a hydrogen atom; or an optionally substituted aromatic ring or an optionally substituted heteroaromatic ring having one or more heteroatoms, a saturated ring optionally having one or more heteroatoms, optionally substituted by an alkyl chain; or a chain having 1-4 atoms, consisting of optionally substituted nitrogen, a carbonyl grouping optionally terminated with an optionally substituted aromatic ring or an optionally substituted heteroaromatic ring optionally having one or more heteroatoms; R3 is a hydrogen atom, a halogen atom, a C1-5 alkyl radical, a nitrogen radical substituted by two groupings that are each independently a hydrogen atom or a C1-5 alkyl grouping optionally incorporating a carbonyl grouping, or an aromatic ring; and R4 is a hydrogen atom, a halogen atom, a C1-5 alkyl radical, or an optionally substituted oxygen-containing derivative, with the exception of 6-phenylamino-5,8-quinolinedione and 2-N-acetylamino-1,4-naphthoquinone.